Last reviewed · How we verify
Phase IV Study Teriparatide and Antiresorptive Combination Treatment Subsequent to 9 Months of Teriparatide Monotherapy (Confors)
Increased bone formation in the absence of accelerated resorption is resulting in a marked anabolic response to teriparatide (TPTD) during the early phase after treatment initiation. Months later, due to coupling mechanism, the sustained increase of bone formation and ongoing anabolic effects are accompanied by significantly increased bone resorption as well. Antiresorptives influence the balance of bone formation and resorption. Therefore the investigators aim is to investigate the effects of the addition of antiresorptives to the second half of TPTD cycle when resorption is already also markedly elevated.
Details
| Lead sponsor | Medical University of Vienna |
|---|---|
| Phase | Phase 4 |
| Status | COMPLETED |
| Enrolment | 125 |
| Start date | 2006-03 |
| Completion | 2012-12 |
Conditions
- Osteoporosis
Interventions
- teriparatide
- teriparatide and raloxifene
- teriparatide and alendronate
Primary outcomes
- Differences in changes of areal lumbar spine BMD between the three treatment groups — Evaluation after 9, 12 and 18 months of TPTD
Primary objective To investigate the changes in lumbar spine BMD of patients among the three treatment groups
Countries
Austria